← All tickers

Is RPRX Worth Buying in 2026?

Royalty Pharma plc Class A Ordinary Shares

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-23

Here’s whether Royalty Pharma plc Class A Ordinary Shares (RPRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.58% over 10 days); strong 1-year return of +68.8%; 3-month momentum positive (+12.5%). Concerns: RSI 71 — overbought, elevated pullback risk. Currently 1.3% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

RPRX is in a confirmed uptrend, trading above both its 50-day ($57.35) and 200-day ($48.08) moving averages. With an RSI of 70.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +68.8% compares to +20.5% for SPY (beat the market by 48.4%).

$10,000 invested 1 year ago → $16,885 today
vs. S&P 500 (SPY) — same period beat market by 48.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($48.08)
✓Above 50-day MA ($57.35)
!RSI(14) neutral zone (30–70) — currently 70.5
✓Positive return (+68.8%)
✓Within 10% of period high (−1.3%)
Period Range $61.31
$34.08 $62.13
RSI (14) 70.5
0 · OversoldOverbought · 100

Key Metrics

Price$61.31
Period Return+68.8%
Period High$62.13
Period Low$34.08
Drawdown−1.3%
MA-50$57.35
MA-200$48.08
RSI (14)70.5
Avg Volume (30d)2.8M
vs. SPYbeat by 48.4%
Return Rank#191 of 999

Trade RPRX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers